Onxeo Buys DNA Repair Technology; Delays PhIII For Validive
This article was originally published in Scrip
Executive Summary
Paris, France-based Onxeo, a company focused on the development of orphan oncology therapeutics, has acquired privately held, clinical-stage biopharmaceutical company DNA Therapeutics for its signal-interfering DNA repair technology and first-in-class molecule.
You may also be interested in...
Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
Femtech Presents Enticing Market Opportunity
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
Execs On The Move, Sep 2020
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Need a specific report? 1000+ reports available
Buy Reports